Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Petre Udrea

Neurology Centerville, OH Medical Doctor

NPI 1245232024 CMS profile 512675

1975 Miamisburg Centerville Rd, Centerville, OH 45459

Open in the dashboard

General payments

$3,557

197 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Petre Udrea of Centerville, OH is reported in the CMS Open Payments database as having received $3,557 across 197 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44 1
2024 General $155 4
2023 General $255 13
2022 General $997 54
2021 General $1,010 50
2020 General $507 34
2019 General $588 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Petre Udrea
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Petre Udrea were reported at $44. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Petre Udrea Neurology median Middle half National median
2019 $588 $474 $118–$2,177 $163
2020 $507 $367 $82–$2,309 $114
2021 $1,010 $438 $104–$2,547 $132
2022 $997 $442 $103–$2,388 $149
2023 $255 $464 $119–$2,312 $160
2024 $155 $468 $119–$2,323 $164
2025 $44 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. EMD Serono, Inc. $571 25 payments
  2. Novartis Pharmaceuticals Corporation $473 37 payments
  3. Biogen, Inc. $428 11 payments
  4. Amgen Inc. $280 16 payments
  5. AbbVie, Inc. $221 14 payments
  6. Supernus Pharmaceuticals, Inc. $111 6 payments
  7. UCB, Inc. $104 6 payments
  8. Pfizer Inc. $99 6 payments
  9. Allergan Inc. $99 6 payments
  10. Teva Pharmaceuticals USA, Inc. $94 6 payments
  11. Other $1,076 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,557 197 payments
Products named General payments · program years 2019–2025
  1. AIMOVIG $439 31 payments
  2. TYSABRI $221 1 payment
  3. KESIMPTA $194 14 payments
  4. NURTEC ODT $111 7 payments
  5. UBRELVY $106 8 payments
  6. Briviact $104 6 payments
  7. TROKENDI XR $98 5 payments
  8. GILENYA $95 6 payments
  9. BOTOX $90 5 payments
  10. TECFIDERA $71 4 payments
  11. Other $1,615 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Psychiatry & Neurology: 100

Drug cost

$173

Median for Psychiatry & Neurology: $2,986

Branded share of claims

0%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ropinirole Hcl Generic 13 $173

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record